XORTX Therapeutics Inc (XORTX) is a drug development company that primarily focuses on orphan disease indications which have a uric acid imbalance as well as metabolic syndrome, diabetes and diabetic nephropathy.
XORTX Therapeutics has three products in clinical development, including XRx-008 for Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease, XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN).
XORTX Therapeutics Inc (XORTX) is a drug development company that primarily focuses on orphan disease indications which have a uric aciduric acid imbalance as well as metabolic syndrome, diabetes and diabetic nephropathy.
XORTX Therapeutics has three products in clinical development, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease, XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic NephropathyDiabetic Nephropathy (T2DN).